Terms: = Lung cancer AND BCL7A, BCL7, 605, ENSG00000110987 AND Treatment
64 results:
1. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Xu K; Lu W; Yu A; Wu H; He J
BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
[TBL] [Abstract] [Full Text] [Related]
2. [Analysis of Influencing Factors of Complications for CT-guided
Percutaneous lung Biopsy].
Wang X; Zhang H; Zhang X
Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):179-186. PubMed ID: 38590192
[TBL] [Abstract] [Full Text] [Related]
3. Association of CCND1 rs9344 polymorphism with lung cancer susceptibility and clinical outcomes: a case-control study.
Mei C; Wang T; Xu B; Wu S; Zhang X; Lv Y; Zhang Y; Liu Z; Gong W
BMC Pulm Med; 2024 Apr; 24(1):167. PubMed ID: 38589850
[TBL] [Abstract] [Full Text] [Related]
4. Patient Age and
Maezawa Y; Taguchi M; Kawakami T; Inui T; Okauchi S; Numata T; Shiozawa T; Miyazaki K; Nakamura R; Iguchi K; Endo T; Sakamoto T; Satoh H; Hizawa N
Anticancer Res; 2024 Apr; 44(4):1751-1757. PubMed ID: 38537995
[TBL] [Abstract] [Full Text] [Related]
5. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell lung cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract] [Full Text] [Related]
6. Polypharmacy and potentially-inappropriate medications are prevalent in the elderly cancer patients receiving systemic cancer therapy and they co-relate with adverse outcomes.
Bandidwattanawong C; Rattanaserikulchai P; Jetsadavanit N
BMC Geriatr; 2023 Nov; 23(1):775. PubMed ID: 38012569
[TBL] [Abstract] [Full Text] [Related]
7. Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
He JZ; Duval V; Jauslin P; Gonçalves A; Abegesah A; Fan C; Lim K; Song X; Chen C; Shi X; Mann H; Krug L; Ren S; Phipps A; Gibbs M; Zhou D
Clin Pharmacol Ther; 2023 Dec; 114(6):1375-1386. PubMed ID: 37777827
[TBL] [Abstract] [Full Text] [Related]
8. Patlak-Ki derived from ultra-high sensitivity dynamic total body [
Wang D; Qiu B; Liu Q; Xia L; Liu S; Zheng C; Liu H; Mo Y; Zhang X; Hu Y; Zheng S; Zhou Y; Fu J; Chen N; Liu F; Zhou R; Guo J; Fan W; Liu H
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3400-3413. PubMed ID: 37310427
[TBL] [Abstract] [Full Text] [Related]
9. Using 3D deep features from CT scans for cancer prognosis based on a video classification model: A multi-dataset feasibility study.
Chen J; Wee L; Dekker A; Bermejo I
Med Phys; 2023 Jul; 50(7):4220-4233. PubMed ID: 37102270
[TBL] [Abstract] [Full Text] [Related]
10. Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of cancers During Chemoradiation Therapy: Real-World Study.
Kang D; Kim S; Kim H; Lee M; Kong SY; Chang YJ; Sim SH; Kim YJ; Cho J
JMIR Public Health Surveill; 2023 Mar; 9():e44105. PubMed ID: 36884274
[TBL] [Abstract] [Full Text] [Related]
11. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract] [Full Text] [Related]
12. Access to Care Metrics in Stage I lung cancer: Improved Access Is Associated With Improved Survival.
Heiden BT; Eaton DB; Chang SH; Yan Y; Schoen MW; Patel MR; Kreisel D; Nava RG; Samson P; Meyers BF; Kozower BD; Puri V
Ann Thorac Surg; 2022 Nov; 114(5):1810-1815. PubMed ID: 35724700
[TBL] [Abstract] [Full Text] [Related]
13. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract] [Full Text] [Related]
14. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract] [Full Text] [Related]
15. [treatment of Stage Ia Non-small Cell lung cancer in Patients:
Comparison of Ablation and Sub-lobectomy].
Zhao H; Fan K; Wang H; Liu B; Li Y; Tao R; Wang Z; Zhang J; Fu J; Zhang G
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):613-622. PubMed ID: 34256899
[TBL] [Abstract] [Full Text] [Related]
16. Time-varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China.
Wang Z; Mo M; Zhou C; Feng X; Shen J; Ye T; Zhang Y; Hu H; Chen H; Zheng Y
Thorac Cancer; 2021 Jun; 12(11):1699-1707. PubMed ID: 33939309
[TBL] [Abstract] [Full Text] [Related]
17. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract] [Full Text] [Related]
18. Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China.
Xie L; Xu J; Li X; Zhou Z; Zhuang H; Sun X; Liu K; Liu X; Sun K; Wu Y; Gu J; Guo W
BMC Cancer; 2021 Mar; 21(1):337. PubMed ID: 33789614
[TBL] [Abstract] [Full Text] [Related]
19. Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
Oselin K; Pisarev H; Ilau K; Kiivet RA
BMC Cancer; 2021 Mar; 21(1):274. PubMed ID: 33722202
[TBL] [Abstract] [Full Text] [Related]
20. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract] [Full Text] [Related]
[Next]
